Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICE: Nimotuzumab with Chemoradiation for Esophageal Cancer
NCT01249352Phase 3Completed
- Sponsor
- Eurofarma
- Start
- Jan 2009
- Primary completion
- Nov 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in esophageal cancer, sponsored by Eurofarma. Started Jan 2009; status: completed.
02
Drugs
nimotuzumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT01249352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01249352.